Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone Regimens for Preventing Paclitaxel Hypersensitivity
NCT03598426Phase 3Completed
- Sponsor
- Loma Linda University
- Start
- Aug 2018
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexamethasone in Hypersensitivity reaction (3 arms), sponsored by Loma Linda University. Primary endpoints: Number Participants With Any-grade Paclitaxel-associated Hypersensitivity Reactions During the First Paclitaxel Infusion and Number of Participants With Grade 3 or Higher Paclitaxel-associated Hypersensitivity Reactions During the First Paclitaxel Infusion. Started Aug 2018; status: completed.
02
Drugs
dexamethasone
03
Conditions
Hypersensitivity reaction
Beyond the preview
Go deeper on NCT03598426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03598426.